CTI Clinical Trial and Consulting Services Opens San Francisco, CA Office

FOR IMMEDIATE RELEASE [Cincinnati, OH ~ September 29, 2014]

CTI Clinical Trial and Consulting Services (CTI), a multinational, privately held, full-service contract research organization announces that is has opened an office in San Francisco, California. This is the company's fifth new office opened this year, with several more expected to be announced in the next 12-18 months.

"While we have been working on the West Coast since the company's inception, we felt that it was time to have a physical presence amongst the many biotechnology and health care companies that are headquartered in California," according to Timothy Schroeder, Chief Executive Officer. "The close proximity to innovative companies and research centers across the western half of the United States allows us to continue to add to the CTI team with the deep talent based there. It also enables us to better serve our sponsors and sites located on the West Coast."

CTI has been working for over fifteen years in the drug development industry in North America, Europe, and South America, specializing in clinical research programs involving critically ill patient populations, and has more than 20 offices worldwide to serve more than 80 pharmaceutical, biotechnology, and medical device clients.

About CTI Clinical Trial and Consulting Services

CTI Clinical Trial and Consulting Services is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consulting services from bench to commercialization with a focus on immunology and a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. CTI's focused therapeutic approach provides pharmaceutical, biotechnology and startup firms with clinical and disease area expertise from a unique mix of academic, medical and industry specialists; rich intellectual capital in transplantation, immunology, infectious diseases, hematology, cardiology, nephrology, hepatology, regenerative medicine and rare diseases; flexible study designs that accelerate development programs and deliver high approval ratings that are among the best in the industry; and exceptional global project management and gold standard safety and data management systems that strengthen their program's success potential. Established in 1999 and headquartered in Cincinnati, OH; CTI has offices in North America, Europe and South America.

Media Contact
Allison Schroeder
[email protected]

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.